Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study

Table 2 Epidemiological population: Effects of age and sex on ACB score and CMI

Effect	Category of interest versus reference category	Point estimate of the odds ratio	95% confidence interval (Wald’s type)
A. Effects of age, gender and/or CIRS-G score-related comorbidity index on ACB score
Sex	Female vs. male	0.72	[0.55; 0.94]
Age class	75 years to < 85 years vs. 65 years to < 75 years	1.13	[0.85; 1.50]
Age class	≥ 85 years vs. 65 years to < 75 years	1.79	[1.08; 2.94]
CMI (4 classes)	Quartile 2 CMI 3–4 vs. Quartile 1 CMI 0–2	1.69	[1.13; 2.52]
	Quartile 3 CMI 5–7 vs. Quartile 1 CMI 0–2	2.03	[1.38; 2.99]
	Quartile 4 CMI ≥ 8 vs. Quartile 1 CMI 0–2	3.29	[2.23; 4.86]
B. Effects of age and/or gender on the comorbidity index
Sex	Female vs. male	0.57	[0.44; 0.74]
Age class	75 years to < 85 years vs. 65 years to < 75 years	2.28	[1.74; 2.99]
Age class	≥ 85 years vs. 65 years to < 75 years	2.79	[1.73; 4.51]

Odds ratio point estimates and confidence intervals calculated by comparing the respective category of interest with the reference category for the possible explanatory variables included in the model for the likelihood of having an anticholinergic burden (A) or a comorbidity index of > 4 (B)

ISSN: 1471-2490